Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Inhibition of tau neuronal internalization using anti-tau single domain antibodies

2 Apr 2025

Abstract excerpt

Abstract In Alzheimer’s disease, tau pathology spreads across brain regions as the disease progresses. Intracellular tau can be released and taken up by nearby neurons. We evaluated single domain anti-tau antibodies, also called VHHs, as inhibitors of tau internalization. We identified three VHH inhibitors of tau uptake: A31, H3-2, and Z70mut1. These VHHs compete with the membrane protein LRP1, a major receptor...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Alzheimer's disease research and treatments
Share to Cellular transport and secretion
Share to Neuroscience and Neuropharmacology Research

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 40175345
DOI: 10.1038/s41467-025-58383-4

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Inhibition of tau neuronal internalization using anti-tau single domain antibodiesPMID 40175345Read ↗

Single Domain Antibody Fragments as New Tools for the Detection of Neuronal Tau Protein in Cells and in Mice StudiesSemantic proximity Read ↗

Inhibition of Tau seeding by targeting Tau nucleation core within neurons with a single domain antibody fragmentSemantic proximity Read ↗

Anti-tau single domain antibodies clear pathological tau and attenuate its toxicity and related functional defectsSemantic proximity Read ↗

Pre-clinical characterisation of E2814, a high-affinity antibody targeting the microtubule-binding repeat domain of tau for passive immunotherapy in Alzheimer’s diseaseSemantic proximity Read ↗

Anti-tau intrabodies: From anti-tau immunoglobulins to the development of functional scFv intrabodiesSemantic proximity Read ↗

Peptide-based inhibitors of Tau aggregation as a potential therapeutic for Alzheimer’s disease and other TauopathiesSemantic proximity Read ↗

Development of a pan‐tau multivalent nanobody that binds tau aggregation motifs and recognizes pathological tau aggregatesSemantic proximity Read ↗

Anti-tau single domain antibodies clear pathological tau and attenuate its toxicity and related functional defectsSemantic proximity Read ↗

Selective Targeting of Pathogenic Tau Seeds via a Novel VHHSemantic proximity Read ↗

Anti-tau VHH therapy against PHF6: a safe approach to slowing the phenotype of tau pathology.Semantic proximity Read ↗

Single-Domain Antibody-Based Autophagosome-Targeting Chimera for Tau Clearance and Motor Function Restoration in TauopathiesSemantic proximity Read ↗

Conformation-based detection of tau seeds with a novel VHHSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.